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Abstract 
Modification of immunoglobulin G (IgG) 1 proteins in cancer treatment is a rapidly growing field of 
research. Antibody–drug conjugates (ADCs) exploit the targeted nature of this immunotherapy by 
conjugating highly potent drugs to antibodies, allowing for effective transport of cargo(s) to 
cancerous cells. Of the many bioconjugation strategies now available for the formation of highly 
homogenous ADCs, disulfide modification is considered an effective, low-cost and widely accepted 
method for modifying IgG1s for improved clinical benefit. However, little is known about how 
disulfide modification impacts clinically relevant fragment crystallisable (Fc) region interactions. 
Although often overlooked as a secondary ADC function, Fc interactions could prove key in rational 
design of cancer cell-targeting ADCs through consideration of potent mechanisms such as antibody-
dependant cellular cytotoxicity (ADCC). This work explores different IgG1 disulfide modification 
techniques and the effect they have on quantifiable secondary IgG1 Fc interactions (e.g. CD16a and 
FcRn). The solvent accessible disulfide residues of trastuzumab, a clinically relevant IgG1, were 
modified to provide a range of bioconjugates with differing amounts of inter-chain covalent linkages. 
It was found that by natively re-bridging the IgG1 model, all tested Fc functionalities were not 
significantly affected. Additionally, in non Fc-specific biophysical experiments (e.g. thermal 
stability/aggregation), the natively re-bridged species provided an exceptional profile, showing no 
significant change from the tested native antibody. Conjugates with significant disruption of the 
covalent connectivity of IgG1 chains resulted in a suboptimal Fc profile (CD16a kinetics or ADCC 
activity), in addition to sub-standard non Fc-specific attributes (thermal stability). These results 
advocate native disulfide re-bridging as an excellent synthetic strategy for forming homogenous IgG1 
bioconjugates, with no reported negative impact on biophysical profile relative to the native 
antibody. 
Introduction 
Protein modification has become a fundamental tool in the preparation of active biomolecules for 
cancer treatment.1,2 More specifically, modification of native monoclonal antibodies (mAbs) allows 
for targeted delivery of highly potent drugs to cancer cells, in the form of antibody–drug conjugates 
(ADCs).3,4 To date, four ADCs have been approved for use by the US Food and Drug Administration 
(FDA) (MylotargTM, BesponsaTM, KadcylaTM, and AdcetrisTM) with over 60 more currently being 
evaluated in clinical trials.5–11 Modification of native amino acid residues has been utilised for the 
majority of the clinically relevant ADCs thus far, likely owing to the lower costs of manufacture. 
Typically, the natural amino acids targeted for site-selective modification are lysine and cysteine 
residues - for their highly nucleophilic ε-amino and thiol groups respectively.2 Cysteine residues are 
often preferred in the synthesis of homogenous antibody conjugates as lysine modification reagents 
(e.g. N-hydroxysuccinimide esters) randomly conjugate over ca. 40 lysine residues on a typical 
IgG1.12 This can result in a heterogeneous mixture of conjugates with a poorly defined 
pharmacokinetic profile (e.g. clearance rates, binding activities etc.), leading to a narrower 
therapeutic window when compared to an analogous homogeneous conjugate.13–16 Due to the low 
natural abundance of cysteine in IgG1 antibodies (i.e. only available through reduction of solvent 
accessible inter-chain disulfides), the highly reactive thiol moiety is an attractive option in the 
formation of homogenous ADCs.17 By reducing the four solvent accessible disulfide bonds (2), it is 
possible to react the liberated thiol groups in a site-selective fashion to obtain an ADC (3) with up to 
eight payloads (thiol capping – Figure 1a). However, depending on the payload employed by the 
desired ADC, lower drug–to-antibody ratios (DARs) are often preferred. A DAR of two to four is 
typically selected in ADC design due to the optimal balance between renal clearance and potency 
being in this range, generally.18 Consequently, capping strategies often target lower DARs by 
reducing an average of 2 disulfides (4, Figure 1b), although heterogeneity issues arise from reduction 
of more/less disulfides than intended (5, Figure 1b).9,19 
Following reduction of the  solvent accessible disulfides, it is  also possible to re-bridge with a 
chemical modification to reform the IgG covalent linkage (6, disulfide re-bridging – Figure 1c).20–22 
Highly homogenous ADCs with a DAR of two or four have been obtained via this strategy, and these 
show no decrease in antigen-binding and no decrease in circulation half-life.23–25 However, it has 
been observed that these disulfide residues can re-bridge in a non-native fashion, resulting in the 
“half-antibody” species 7, thus yielding a mixture of two antibody conjugates (Figure 1c).26,27a,27b 
Currently there have been no studies to suggest this “half-antibody” species (7) negatively affects 
the profile of the antibody. Reagents and conditions to reduce the amount of this species in 




Figure 1 –Disulfide modification via reduction of solvent accessible IgG1 disulfides subsequent 
reaction of liberated thiols: a) reduction of all available disulfides and reaction of each liberated thiol 
with capping species, b) partial reduction of disulfide residues and reaction of each liberated thiol 
with capping species, c) reduction of all available disulfides and re-bridging of two liberated thiols 
with re-bridging species. 
Native antibody modification is a powerful tool in the synthesis of ADCs; however, it is also 
considered a highly intricate process with a multitude of antibody functions to preserve post-
conjugation.28–30 Although antigen-binding is defined for each of the conjugation strategies outlined 
above, Fc activity is often overlooked as a secondary interaction. Antibodies targeting cancer cells 
directly can benefit from a potent secondary mechanism such as antibody-dependant cellular 
cytotoxicity (ADCC) (e.g. when an antibody internalises poorly).31 Antibodies with potent Fc function 
may be selected for this reason, as a platform for synthesising an effective ADC (e.g. trastuzumab 
and brentuximab in the synthesis of KadcylaTM and AdectrisTM respectively).9,32 It is therefore 
favourable to develop a conjugation technology which avoids negatively impacting these valuable 
IgG1 functionalities.29,31 
In this work, the influence of disulfide modification on IgG1 Fc activity was explored. For this 
investigation, a small library of IgG1 antibody conjugates was synthesised with varying degrees of 
covalent integrity between antibody chains. The disulfide modified conjugates considered were as 
follows: natively re-bridged 6; disulfide scrambled 7; thiol capped with a maleimide-to-antibody ratio 
of 4 (MAR 4) 5; thiol capped with a maleimide-to-antibody ratio of 8 (MAR 8) 3. For a comparative 
model, the IgG1 antibody trastuzumab 8 was selected as a good representation of an IgG1 platform 
that has been modified for increased clinical benefit (e.g. as observed in the FDA-approved ADC 
KadcylaTM).7 Conjugation to the disulfide residues of trastuzumab has also been well documented, 
using a library of conjugation reagents.20,23–25,27a,33,34 The conjugates synthesised for this work were 
modified with small (<200 Da), chemically similar linkers so that any observable effect on the 
characteristics of the antibody conjugates could be attributed to the method of disulfide 
modification employed. We also had to consider that the antibody conjugates compared in this 
study cover a range of loadings (e.g. comparison between the MAR 4 and MAR 8 conjugates) and 
that this large variation in hydrophobic loading would significantly affect (and potentially dominate) 
properties. Moreover, work presented in the literature (e.g. Gieseler and co-workers (Mol. Pharm., 
2018); Jackson and co-workers (Mol. Pharm., 2015); Senter and co-workers (Nat. Biotechnol., 2015)) 
has highlighted how properties of ADCs can vary based on the nature of the cargo; thus by adding 
minimal and similar functionality to each linker we focussed on how each disulfide modification 
technique, at a core-level, affects properties.18,35a-c Two key and quantifiable Fc interactions formed 
the focus of our investigation, CD16a and FcRn, which provide relevant information regarding ADCC 
and FcRn recycling respectively.36 
Results 
Controlled manipulation of IgG1 disulfide bonds 
Trastuzumab conjugates 12-15 were synthesised (2 disulfide re-bridged and 2 thiol capped 
bioconjugates) displaying a wide range of intact disulfides and homogeneity (Figure 2). All 
conjugates were analysed by LC-MS, and the relative amount of the products formed under each set 
of conjugation conditions was approximated by densitometry analysis (SDS-PAGE, Figure 2). 
Trastuzumab 8 was natively re-bridged with ethyl alkyne dibromopyridazinedione 9 (diBr PD) to form 
a fully modified antibody conjugate 12 (ca. 90% homogenous by densitometry) by employing 
previously reported protocols (Figure 2a).21 
To form a heterogeneous re-bridged trastuzumab conjugate, a new protocol was established 
through employment of a novel PD derivative – dichloro (DiCl) PD (10). In previous reports, it has 
been hypothesised that the liberated cysteines from disulfides could have a greater tendency to re-
bridge in a non-native conformation if fully reduced prior to addition of the re-bridging reagent.20,21 
Therefore, the inter-chain disulfides of trastuzumab were reduced for 2 h prior to the addition of a 
re-bridging agent. In addition, a less reactive re-bridging agent was sought, to increase the thiol 
residency times after reaction of one thiol. It was found that by using an ethyl alkyne DiCl PD (10) to 
re-bridge the disulfides of trastuzumab 8, a heterogeneous bioconjugate 13 with ca 50 % of the half-
antibody species was obtained (Figure 2b) (quantified by densitometry, see Figure S7 in Supporting 
Information).  
Two separate thiol capped trastuzumab conjugates (14 and 15) were also synthesised for 
comparison, demonstrating full and partial deconstruction of IgG1 disulfide covalent inter-chain links 
(producing maleimide-antibody ratios (MARs) of 8 and 4 respectively). For the formation of the thiol 
capped (MAR 8) conjugate 15, an excess of reducing agent (25 eq.) was added followed by an excess 
of N-propargyl maleimide 11 (25 eq.) (Figure 2d). For the synthesis of the thiol capped (MAR 4) 
species 14, only 2 equivalents of reducing agent were added and left to react until completion 
overnight, before addition of excess maleimide (25 eq.) (Figure 2c). To confirm a MAR of 4 (in 
addition to reduced MS analysis), a copper assisted azide–alkyne cycloaddition (CuAAC) reaction was 
carried out on the resultant conjugate to confirm a fluorescent loading of 4 (AlexaFluorTM-488) by 
UV-Vis spectrometry (see Figure S11 in Supporting Information). 
 
Figure 2 – Synthesis of trastuzumab conjugates, structures of most abundant species shown. All 
steps carried out in BBS pH 8.0, 0.25 mM EDTA: a) ethyl alkyne diBr PD 9 (20 eq.), TCEP (12 eq.), 4 °C, 
16 h; b) i) TCEP (25 eq.), 37 °C, 2 h. ii) ethyl alkyne diCl PD 10 (25 eq.), 37 °C, 4 h; c) i) TCEP (2 eq.), 
37 °C, 16 h. ii) propargyl maleimide 11 (25 eq.) 21 °C, 16 h; d) i) TCEP (25 eq.), 37 °C, 2 h. ii) propargyl 
maleimide 11 (25 eq.) 21 °C, 16 h. SDS PAGE analysis of trastuzumab 8 and trastuzumab conjugates 
12-15. 
Trastuzumab-FcRn Assays 
An FcRn bio-layer interferometry (BLI) assay was designed to mimic FcRn recycling. To demonstrate 
early endosomal binding conditions, the assay initially explored association and dissociation at 
pH 6.0 to provide an approximate, comparative KD for each synthesised conjugate. Additionally, 
mimicking release of the conjugate from FcRn in blood plasma, dissociation was monitored at pH 
7.4. Due to the robust nature of the FcRn, it was recycled 3 times before discarding, showing little 
decrease in binding affinity. A single point concentration was selected for the comparative assay, to 
avoid complications with global fit analysis (stemming from the dimeric nature of the IgG1-FcRn 
interaction) similar to previous literature reports.37 
None of the tested conjugates exhibited an approximate KD significantly different from the 
unmodified trastuzumab control 8 (Figure 3a), and no change to the dissociation rate at pH 7.4 was 
observed (Figure 3b). These results therefore suggest inter-chain disulfide residues are not likely to 
be involved in FcRn interactions, and that the integrity of inter-chain covalent links would not likely 
affect the FcRn recycling mechanism of IgG1 antibodies.  
 
Figure 3 – Trastuzumab – FcRn BLI assay results summary. a) Average approximate KD values 
obtained at pH 6.0; b) Average koff values obtained at pH 7.4. 
Trastuzumab-CD16a Assays 
A comparative BLI assay was also designed to monitor any changes in CD16a kinetics of the 
synthesised conjugates. The optimal platform employed streptavidin sensors loaded with 
biotinylated CD16a, which produced reliable results consistent with literature reports.33 
The kinetic data obtained for the disulfide modified conjugates followed a general trend relating to 
covalent inter-chain connectivity. Importantly, natively re-bridged trastuzumab 12 showed very little 
deviation from the unmodified control 8, whilst fully thiol capped trastuzumab 15 had a ten-fold 
increase in KD (i.e. decrease in binding, Figures 4a and 4b). The disulfide scrambled conjugate 13 also 
appeared to yield a similar KD to the natively re-bridged trastuzumab 12, whilst the partially capped 
trastuzumab 14 afforded a marginally higher, yet reproducible, KD (Figures 4a and 4b). These results 
highlight the native disulfide re-bridging strategy to have little to no effect on CD16a KD values. 
Furthermore, the general trend observed between these conjugates suggests intact IgG1 inter-chain 
covalent links may play a significant role in IgG1-CD16a kinetics. 
 Figure 4 – Trastuzumab – FcRn BLI kinetics and ADCC cell kill assay summary. a) Maximum response 
at varying concentrations of Trastuzumab (8)/Trastuzumab conjugates (12-15). b) Average 
Trastuzumab (8)/Trastuzumab conjugates (12-15)– CD16a KD values (see Table S5 in Supporting 
Information for details). c) ADCC dose response curves for Trastuzumab (8)/Trastuzumab conjugates 
(12-15) with EC50 values.  
To confirm the significance of the CD16a KD values obtained in the BLI assays, the synthesised 
conjugates were also subjected to an ADCC cell killing assay. BT-474 cells were incubated with each 
of the synthesised conjugates before adding CD16a+ NK-92 cells. Surprisingly, the conjugate 
repeatedly showing the least cell kill was the disulfide scrambled species 13. As this did not align 
with the trends observed in CD16a kinetics, it was anticipated this type of modification confers an 
unfavourable change in IgG1 interactions outside of the tested kinetic model (immobilised CD16a-
trastuzumab). Despite a significant increase in KD for some conjugates, all other tested species 
showed little decrease in ADCC activity. Whilst kinetic data is not always a good representation of 
what to expect in ADCC assays38, it is evident all types of disulfide modification affected either 
trastuzumab CD16a kinetics (thiol capped conjugates 14 and 15), or ADCC activity (disulfide 
scrambled conjugate 13) – with the exception of the natively re-bridged species 12. 
Additional biophysical assays 
In addition to the results on IgG1 Fc function, a general biophysical profile was sought for each of the 
synthesised conjugates. In addition to native trastuzumab 8, the disulfide modified conjugates (12-
15) were compared in terms of antigen-binding, thermal stability and aggregation. These 
experiments were designed to provide a deeper understanding of the total influence that inter-chain 
covalent linkage integrity may have on other relevant antibody characteristics. 
Thermal stability: 
In a comparative experiment, melting temperatures (i.e. Tm values) were calculated for each of the 
trastuzumab conjugates by conducting a thermal shift assay. Generally, a trend in intact inter-chain 
covalent links was established as the thiol capped conjugates 14 and 15 showed a linear decrease in 
Tm. Pleasingly, the natively re-bridged conjugate 12 had minimal change to the Tm, when compared 
with the native antibody 8 (Table 1). Unexpectedly, the disulfide scrambled conjugate 13 had a 
comparable Tm to the thiol capped conjugate (MAR 4) 14 despite having a large proportion of the 
interchain disulfides correctly re-bridged (as 14 exists as a mixture of conjugates). We postulate that 
this may be indicative of an unstable conformation adopted by re-bridging the IgG1 disulfides in a 
non-native conformation.  
SEC-MALS: 
Approximate masses and polydispersity of the conjugate samples were compared with the intention 
of quantifying the amount of aggregate present, after bioconjugate synthesis. All tested conjugates 
yielded an insignificant percentage of aggregate by SEC-MALS. The disulfide scrambled conjugate 13 
showed the most aggregation, with 2% of the mass being polydisperse, although this level of 
aggregate is not thought to be significant enough to affect antibody function (Table 1). Notably, 
natively re-bridging the disulfide residues showed no impact in terms of tendency to aggregate (see 
Table S8 in Supporting Information). 
Enzyme-linked Immunosorbent Assay (ELISA): 
Human epidermal growth factor (HER2) affinity was also measured for the synthesised conjugates, 
to confirm antigen-binding activity. All conjugates showed little deviation from the native 
trastuzumab control 8, which performed as expected, in accordance with previously reported results 
(see Figure S16 in Supporting Information).21  
Table 1 Summary of additional biophysical data depicting percentage of sample considered 
aggregate by polydispersity; Thermal shift assays melting temperature (Tm) values; calculated IC50 
vales for trastuzumab – HER2 ELISA. 
Trastuzumab Conjugate Aggregate mass 
fraction (%) 
Tm Value (⁰C) HER 2 IC50 (M) 
Trastuzumab 8 0.5 85.3 ± 0.06 6.783 × 10-10 
Natively re-bridged 12 0.9 84.6 ± 0.62 5.837 × 10-10 
Disulfide scrambled 13 2.2 81.8 ± 0.24 4.530 × 10-10 
Thiol capped (MAR 4) 14 0.2 81.7 ± 0.08 5.419 × 10-10 
Thiol capped (MAR 8) 15 0.7 78.5 ± 0.49 5.397 × 10-10 
 
Conclusion 
This work represents the first example of appraising the Fc function of typical IgG1 bioconjugates 
formed via interchain disulfide-based modification strategies (including re-bridging and non-
rebridging methods) in a single study; thermal stability, aggregation and antigen-binding were also 
measured on the same conjugates. CD16a and FcRn interactions were chosen to quantify effects of 
disulfide modification on trastuzumab (i.e. a model IgG1), which was achieved by use of BLI assays, 
and subsequent in vitro assays (i.e. ADCC) where applicable. The natively re-bridged IgG1 conjugate 
performed exceedingly well with no apparent decrease in CD16a or FcRn binding affinity, as well as 
no significant decrease in ADCC activity, suggesting re-bridging in a native conformation has minimal 
effect on IgG1 Fc function. It was found that by re-bridging the disulfides in a non-native 
conformation, whilst not affecting CD16a kinetics, did negatively influence the ADCC activity of the 
conjugate. Conversely, fully reducing and capping the disulfides of trastuzumab significantly affected 
the CD16a kinetics but did not yield significantly different ADCC results from the trastuzumab 
control. Further biophysical analysis of these conjugates (aggregation tendencies, thermal stability, 
antigen-binding) definitively showed that natively re-bridging the disulfide residues was the only 
modification strategy to have no negative impact on biophysical profile relative to the native 
antibody. This study therefore highlights the importance of the nature of disulfide modification on 
various properties and that natively re-bridging the disulfides appears to be the best way to retain 
the key properties of the native antibody. Moreover, through publishing the complexity of these 
secondary IgG1 mechanisms in a single study (e.g. CD16a binding is not necessarily correlated to 
ADCC activity), it is envisaged that more efforts will be stimulated into understanding the 
relationship between antibody conjugation and Fc interactions. 
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